Leucine Rich Bio is a company focused on human genome interpretation for clinical and research use. They utilize advances in computer science, data management, and systems biology to analyze genomic data and develop solutions for drug discovery. Their current efforts involve using system biology and big data approaches to identify novel disease targets. They are seeking partnership opportunities to further their mission.
Dr. Daniel Linhares - Growing Pig Impact, Assessing Impact of 1-7-4 PRRSv on ...John Blue
Growing Pig Impact, Assessing Impact of 1-7-4 PRRSv on Wean to Finish Pig Health - Dr. Daniel Linhares, from the 2015 Allen D. Leman Swine Conference, September 19-22, 2015, St. Paul, Minnesota, USA.
More presentations at http://www.swinecast.com/2015-leman-swine-conference-material
Leveraging Publicly Accessible Clinical Trails Data Sharing, Dissemination an...Vaticle
In the broader realm of the advancement of science and the betterment of the human condition, there are several purported benefits for sharing clinical trials and research data. The scientific community has just begun to embrace open-access datasets to build their knowledge base, gain insight into new discoveries, and generate novel data-driven hypotheses that were not initially formulated in the studies. With the increasing amount of clinical trial data available, comes the need to leverage a multitude of shared datasets. Your knowledge base needs to facilitate discovery across research domains.
This talk highlights the data sharing, dissemination, and repurposing of clinical and molecular studies generated by government-funded research consortia. Further, we are building a new knowledge base resource, IMMGRAKN to facilitate translational discovery from crowd-sourced clinical trials data in ImmPort (www.immport.org), an NIH-NIAID funded open-access immunology database and analysis portal. The case studies demonstrating the use of IMMGRAKN will be discussed
Describes SciBites unique text mining technology for embedding in applications and data mining use cases within pharma , biotech and life science industry
An invited talk for Lilly's Global IT Seminar Meeting In November 2016 on the subject of data, machine learning, AI, semantic web, text mining and spinach!
Before assessing the clinical significance of a somatic mutation, one must determine if the mutation is likely to be a driver mutation (i.e. a mutation that provides a selective growth advantage, thereby promoting cancer development). To aid clinicians in this process, VSClinical provides an oncogenicity scoring system, which uses a variety of metrics to classify a given somatic mutation into one of the following categories: oncogenic, likely oncogenic, benign, likely benign, or uncertain significance. This scoring system is heavily inspired by the ACMG Guidelines for the interpretation of germline mutations but has several important differences to make it more applicable in the context of somatic variant interpretation.
Our oncogenicity scoring system relies on an additive point system in which points are assigned to a given variant based on several criteria. Many of the criteria are shared by the ACMG Guidelines for germline variant interpretation, such as population frequency information, variant effect on protein function, and nearby pathogenic variants in catalogs such as ClinVar. However, other criteria are specific to the world of somatic variant interpretation. These include the variant’s presence in somatic catalogs such as COSMIC, the effect of other known oncogenic variants in the same gene, and the variant’s presence in known cancer hotspots or active binding sites. These criteria are combined by summing over the scores for all applicable scoring criteria. Scores exceeding 3 indicate an oncogenic or likely oncogenic classification, while scores falling below -3 indicate a benign or likely benign classification.
In this webcast, we discuss how each of these scoring criteria are combined to obtain an oncogenicity classification. This includes a discussion of the considerations taken into account during the development of this scoring system and a detailed analysis of several example mutations to illustrate the system in practice.
RESEARCH GOAL:
To establish how the topic of sustainability is perceived and represented by corporations contrary to the mass audience opinion across the globe.
Dr. Daniel Linhares - Growing Pig Impact, Assessing Impact of 1-7-4 PRRSv on ...John Blue
Growing Pig Impact, Assessing Impact of 1-7-4 PRRSv on Wean to Finish Pig Health - Dr. Daniel Linhares, from the 2015 Allen D. Leman Swine Conference, September 19-22, 2015, St. Paul, Minnesota, USA.
More presentations at http://www.swinecast.com/2015-leman-swine-conference-material
Leveraging Publicly Accessible Clinical Trails Data Sharing, Dissemination an...Vaticle
In the broader realm of the advancement of science and the betterment of the human condition, there are several purported benefits for sharing clinical trials and research data. The scientific community has just begun to embrace open-access datasets to build their knowledge base, gain insight into new discoveries, and generate novel data-driven hypotheses that were not initially formulated in the studies. With the increasing amount of clinical trial data available, comes the need to leverage a multitude of shared datasets. Your knowledge base needs to facilitate discovery across research domains.
This talk highlights the data sharing, dissemination, and repurposing of clinical and molecular studies generated by government-funded research consortia. Further, we are building a new knowledge base resource, IMMGRAKN to facilitate translational discovery from crowd-sourced clinical trials data in ImmPort (www.immport.org), an NIH-NIAID funded open-access immunology database and analysis portal. The case studies demonstrating the use of IMMGRAKN will be discussed
Describes SciBites unique text mining technology for embedding in applications and data mining use cases within pharma , biotech and life science industry
An invited talk for Lilly's Global IT Seminar Meeting In November 2016 on the subject of data, machine learning, AI, semantic web, text mining and spinach!
Before assessing the clinical significance of a somatic mutation, one must determine if the mutation is likely to be a driver mutation (i.e. a mutation that provides a selective growth advantage, thereby promoting cancer development). To aid clinicians in this process, VSClinical provides an oncogenicity scoring system, which uses a variety of metrics to classify a given somatic mutation into one of the following categories: oncogenic, likely oncogenic, benign, likely benign, or uncertain significance. This scoring system is heavily inspired by the ACMG Guidelines for the interpretation of germline mutations but has several important differences to make it more applicable in the context of somatic variant interpretation.
Our oncogenicity scoring system relies on an additive point system in which points are assigned to a given variant based on several criteria. Many of the criteria are shared by the ACMG Guidelines for germline variant interpretation, such as population frequency information, variant effect on protein function, and nearby pathogenic variants in catalogs such as ClinVar. However, other criteria are specific to the world of somatic variant interpretation. These include the variant’s presence in somatic catalogs such as COSMIC, the effect of other known oncogenic variants in the same gene, and the variant’s presence in known cancer hotspots or active binding sites. These criteria are combined by summing over the scores for all applicable scoring criteria. Scores exceeding 3 indicate an oncogenic or likely oncogenic classification, while scores falling below -3 indicate a benign or likely benign classification.
In this webcast, we discuss how each of these scoring criteria are combined to obtain an oncogenicity classification. This includes a discussion of the considerations taken into account during the development of this scoring system and a detailed analysis of several example mutations to illustrate the system in practice.
RESEARCH GOAL:
To establish how the topic of sustainability is perceived and represented by corporations contrary to the mass audience opinion across the globe.
To support research and development in different stages of biopharmaceutical compounds and products, QPS offers biomarker services in different global competence centers using
a wide range of technology platforms to support programs in any therapeutic area. QPS biomarker capabilities range from small molecule analysis to whole cell characterization.
According to a 2016 Nature survey, more than 70% of researchers have failed to reproduce another scientist’s experiments. To solve the reproducibility problem, the research community demands high-quality biobanks to deliver fit-for-purpose biospecimens – key pillars advancing science in medicine. Precision for Medicine is a global leader in supplying diverse, high quality, IRB-approved, clinically annotated, ready-to-ship human biospecimens.
This talk provides an insider’s look into Precision for Medicine’s variant-rich biobank showcasing biospecimen types, highlighting usage, custom collection solutions and disease-matched control sets across multiple therapeutic areas. Precision for Medicine’s biorepository contains diverse, genetically characterized specimens validated using various NGS assays and platforms.
Described in this talk are just some of the sample types, screening methods, and subsequently the integrated QuartzBio database of variants found. The speakers also discuss Precision for Medicine’s partnership capabilities, such as for supporting companion diagnostic development including inter-laboratory reproducibility, validation kit assembly and prospective collections for matched tissue types, minimal residual disease, and clinical trial enrollment.
Key Topics Include:
- Gain a broad understanding of Precision for Medicine, Biospecimen Solutions variant-rich biobank contents pertaining to different therapeutic areas
- Become familiar with fit-for-purpose human biospecimens, their diverse types and appropriate uses
- Become acquainted with the biospecimen characterization data available from Precision for
Medicine, Biospecimen Solutions
- Discover the various partnership options for sample and patient screening for R&D and CDx development and clinical trial enrollment
- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca
- Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets
- Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers
-Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development
- Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme
How AstraZeneca is Applying AI, Imaging & Data Analytics (AI-Driven Drug Deve...Nick Brown
Keynote AI Presentation given at AI-Driven Drug Development Summit Europe on 26th April 2023 in London. Overview around how AstraZeneca has been developing AI in the past 5+ years. Predominantly focused on R&D and how we are developing digital solutions & AI for right safety and right dose. AI examples include machine learning for safety assessment, augmenting digital pathology for image quantification & segmentation, understanding more about our drugs through advanced imaging modalities and first steps in applying AI for right dose - immunogenicity, adverse events and tolerability.
R&D
Drug Development
Diagnosis
Disease Prevention
Epidemic prediction
Remote Monitoring
Manufacturing
Marketing
Wrapping up
How is AI used in the pharmaceutical industry?
How does AI help in drug discovery?
Will AI lead to cheaper and better medications?
Discovery on Target 2014 - The Industry's Preeminent Event on Novel Drug TargetsJaime Hodges
Cambridge Healthtech Institute's 12th Annual Discovery on Target will showcase current and emerging “hot” targets for the pharmaceutical industry, October 8 – 10, 2014 in Boston, MA. Spanning three days, the meeting will bring together more than 900 global attendees, including scientists/technologists, executives, directors, and managers from biopharma, academic, and healthcare organizations. In 2014 the event is comprised of 14 conference tracks which include Epigenetic Readers, Ubiquitin Proteasome, Big Data Discovery, GPCR Drug Discovery, RNAi-Screens-Functional-Genomics, PPI Targets, Protein-Targets, Histone-Methyltransferases-Demethylases, Drug Transporters, Maximizing Efficiency, GPCR Therapeutics, Genomics Screening, Cancer Metabolism and Membrane Production. The 2014 event will offer 200+ scientific presentations across 14 conference tracks, 1 Symposium and 15 conference short courses, 40+ interactive breakout discussion groups, an exhibit hall of 40+ companies, and dedicated poster viewing and networking sessions.
The Pistoia Alliance is examining the challenges of the Faster Safe Companion Diagnostics (CDx) by Aligning Discovery & Clinical Data in the Regulatory Domain.
The slides discuss whether the data standards used in the research environment be aligned better with the data standards used in the regulated environment? If so, the time and cost of the development of NGS-based CDx could be reduced.
Whether your focus is on small molecules, proteins, bio-therapeutics, vaccines, or gene therapy, QPS provides a full range of bioanalytical solutions to support drug development from discovery through clinical development and filing.
"Hacking the Software for Life" - Brad Perkins (Chief Medical Officer, Human ...Hyper Wellbeing
"Hacking the Software for Life" - Brad Perkins (Chief Medical Officer, Human Logevity, Inc.)
Delivered at the inaugural Hyper Wellbeing Summit, 14th November 2016, Mountain View, California.
For more information including details of subsequent events, please visit http://hyperwellbeing.com
The summit was created to foster a community around an emerging industry - Wellness as a Service (WaaS). Consumer technologies, in particular wearables and mobile, are powering a consumer revolution. A revolution to turn health and wellness into platform delivered services. A revolution enabling consumer data-driven disease risk reduction. A revolution extending health care past sick care towards consumer-led lifelong health, wellness and lifestyle optimization.
WaaS newsletter sign-up http://eepurl.com/b71fdr
@hyperwellbeing
Cell & Gene Therapy Preclinical Development SolutionsCovance
Cell & Gene Therapy preclinical development solutions to reduce scientific, regulatory and commercial risks, and accelerate development wherever you are in your product's development.
To support research and development in different stages of biopharmaceutical compounds and products, QPS offers biomarker services in different global competence centers using
a wide range of technology platforms to support programs in any therapeutic area. QPS biomarker capabilities range from small molecule analysis to whole cell characterization.
According to a 2016 Nature survey, more than 70% of researchers have failed to reproduce another scientist’s experiments. To solve the reproducibility problem, the research community demands high-quality biobanks to deliver fit-for-purpose biospecimens – key pillars advancing science in medicine. Precision for Medicine is a global leader in supplying diverse, high quality, IRB-approved, clinically annotated, ready-to-ship human biospecimens.
This talk provides an insider’s look into Precision for Medicine’s variant-rich biobank showcasing biospecimen types, highlighting usage, custom collection solutions and disease-matched control sets across multiple therapeutic areas. Precision for Medicine’s biorepository contains diverse, genetically characterized specimens validated using various NGS assays and platforms.
Described in this talk are just some of the sample types, screening methods, and subsequently the integrated QuartzBio database of variants found. The speakers also discuss Precision for Medicine’s partnership capabilities, such as for supporting companion diagnostic development including inter-laboratory reproducibility, validation kit assembly and prospective collections for matched tissue types, minimal residual disease, and clinical trial enrollment.
Key Topics Include:
- Gain a broad understanding of Precision for Medicine, Biospecimen Solutions variant-rich biobank contents pertaining to different therapeutic areas
- Become familiar with fit-for-purpose human biospecimens, their diverse types and appropriate uses
- Become acquainted with the biospecimen characterization data available from Precision for
Medicine, Biospecimen Solutions
- Discover the various partnership options for sample and patient screening for R&D and CDx development and clinical trial enrollment
- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca
- Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets
- Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers
-Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development
- Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme
How AstraZeneca is Applying AI, Imaging & Data Analytics (AI-Driven Drug Deve...Nick Brown
Keynote AI Presentation given at AI-Driven Drug Development Summit Europe on 26th April 2023 in London. Overview around how AstraZeneca has been developing AI in the past 5+ years. Predominantly focused on R&D and how we are developing digital solutions & AI for right safety and right dose. AI examples include machine learning for safety assessment, augmenting digital pathology for image quantification & segmentation, understanding more about our drugs through advanced imaging modalities and first steps in applying AI for right dose - immunogenicity, adverse events and tolerability.
R&D
Drug Development
Diagnosis
Disease Prevention
Epidemic prediction
Remote Monitoring
Manufacturing
Marketing
Wrapping up
How is AI used in the pharmaceutical industry?
How does AI help in drug discovery?
Will AI lead to cheaper and better medications?
Discovery on Target 2014 - The Industry's Preeminent Event on Novel Drug TargetsJaime Hodges
Cambridge Healthtech Institute's 12th Annual Discovery on Target will showcase current and emerging “hot” targets for the pharmaceutical industry, October 8 – 10, 2014 in Boston, MA. Spanning three days, the meeting will bring together more than 900 global attendees, including scientists/technologists, executives, directors, and managers from biopharma, academic, and healthcare organizations. In 2014 the event is comprised of 14 conference tracks which include Epigenetic Readers, Ubiquitin Proteasome, Big Data Discovery, GPCR Drug Discovery, RNAi-Screens-Functional-Genomics, PPI Targets, Protein-Targets, Histone-Methyltransferases-Demethylases, Drug Transporters, Maximizing Efficiency, GPCR Therapeutics, Genomics Screening, Cancer Metabolism and Membrane Production. The 2014 event will offer 200+ scientific presentations across 14 conference tracks, 1 Symposium and 15 conference short courses, 40+ interactive breakout discussion groups, an exhibit hall of 40+ companies, and dedicated poster viewing and networking sessions.
The Pistoia Alliance is examining the challenges of the Faster Safe Companion Diagnostics (CDx) by Aligning Discovery & Clinical Data in the Regulatory Domain.
The slides discuss whether the data standards used in the research environment be aligned better with the data standards used in the regulated environment? If so, the time and cost of the development of NGS-based CDx could be reduced.
Whether your focus is on small molecules, proteins, bio-therapeutics, vaccines, or gene therapy, QPS provides a full range of bioanalytical solutions to support drug development from discovery through clinical development and filing.
"Hacking the Software for Life" - Brad Perkins (Chief Medical Officer, Human ...Hyper Wellbeing
"Hacking the Software for Life" - Brad Perkins (Chief Medical Officer, Human Logevity, Inc.)
Delivered at the inaugural Hyper Wellbeing Summit, 14th November 2016, Mountain View, California.
For more information including details of subsequent events, please visit http://hyperwellbeing.com
The summit was created to foster a community around an emerging industry - Wellness as a Service (WaaS). Consumer technologies, in particular wearables and mobile, are powering a consumer revolution. A revolution to turn health and wellness into platform delivered services. A revolution enabling consumer data-driven disease risk reduction. A revolution extending health care past sick care towards consumer-led lifelong health, wellness and lifestyle optimization.
WaaS newsletter sign-up http://eepurl.com/b71fdr
@hyperwellbeing
Cell & Gene Therapy Preclinical Development SolutionsCovance
Cell & Gene Therapy preclinical development solutions to reduce scientific, regulatory and commercial risks, and accelerate development wherever you are in your product's development.
1. Research and Development is at the core of
Leucine Rich Bio. We leverage deep
understanding of disease biology and
bioinformatics to embark upon novel in‐
house solutions to drug discovery. Our
current efforts are to utilize system biology
and big data approaches to uncover novel
targets for different diseases. We are also
looking for partners with complimentary
capabilitiestotakeourmissionforward.
Research & Development
Please write to us for more information
or for collaboration at
Interested in our products and services?
Leucine Rich Bio is actively seeking alliance
partners to distribute and promote its
products in South East Asia, Australia, Europe,
MiddleEastandtheAmericas.
Pleasegetintouchwithusat:
partners@leucinerichbio.com
rnd@leucinerichbio.com
Alliance & Partners
Leucine Rich Bio Private Limited
679/57, 30th Cross Jayanagar 4th T block
Bangalore – 560 041
info@leucinerichbio.com www.leucinerichbio.com
Genome Data Analysis
Discover | Decipher | Deliver
Our India Partner
www.leucinerichbio.com
info@leucinerichbio.com
+91 973 909 9468
+91 973 909 9468
2. Leucine Rich Bio’s area of focus is in Human Genome Interpretation,
especially for clinical and research use. We use advances in the area of
Computer Science, Information Science, Data Management, Statistics and
Systems Biology to solve complex problems in Genomics. We envision using
cutting edge big data approaches along with machine learning algorithms to
delve deeper into the understanding of the human genome and develop
novelsolutionstodrugdiscovery.
Company
02
LeucineRichBioPrivateLimited
www.leucinerichbio.com
• Proprietary Analysis Platform
• Multilayered Encrypted Privacy
• Quick Turn Around Time
• Affordable Pricing
For Research
+91 973 909 9468 info@leucinerichbio.com
Small RNA Analysis
Transcriptome Analysis
NGS data can lead to novel
discoveries.If you have performed
an NGS ex‐periment and want to
analyze the data to interpret or
reinterpret the genome and the
transcriptome then Leucine Rich
Bio’s proprietary pipelines can
help achieve your goals in a fast,
accurate and affordable manner.
Genome Analysis
Leucine Rich Bio provides in
depth Genome Analysis. We
provide accurate reports on
variant calling, and de novo
mutations. An automated
analysis pipeline provides high‐
powered genome analysis with
support for the IGV‐ and USCS
browsers as well as VarSifter.
Transcriptome Sequencing
analyses provides information
to detect novel transcribed
regions, splice event, additional
promoters, exons, and 3’
untranscribed regions. We also
help analyse the impact of
transcription on key signalling
pathways.
Leucine Rich Bio’s small RNA
sequencing analysis platform
utilizes powerful algorithms to
study the subset of RNA in
various organisms. We
specialise in discovering novel
miRNA and their potential
targets.
3. Our Technology
04
LeucineRichBioPrivateLimited
Advanced Genome Interpretation Suite
+91 973 909 9468 info@leucinerichbio.comwww.leucinerichbio.com
AGIS (Advanced Genome Interpretation Suite) is a Clinical Data
Analysis Platform for Analyzing and Interpreting Clinically Relevant
Sequence information from Human Genomes. AGIS uses powerful
algorithms to report precise Disease Causing Mutations.
Our proprietary platform AGIS based customized report translates
complex genomic data into clinically relevant and actionable biological
information.
At Leucine Rich Bio we help clinicians appreciate the value of
Personalized Medicine. AGIS’ powerful algorithms eliminate the bottle
neck in data analysis and interpretation of Genomic Data for
Healthcare providers. AGIS provides end to end data Interpretation
Solutions.
AGIS interface and algorithms are designed to provide information in a
fast yet accurate manner. AGIS outputs physician ready reports. AGIS has
undergone extensive in‐silico validation testing for its accuracy and
consistency (sensitivity 98%; specificity 96%).
Our in house manually curated (Human Genome VariationLRB‐HGVD
Database) provides functional information, mutation impact on
disease, drug response and variant impact on protein structure and
function. LRB‐HGVD is tailored to provide variant functional
information to AGIS.
AGIS uses an advanced intuitive ranking system to identify clinically
relevant variants. The proprietary ranking algorithm is highly effcient to
identify complex range of variants including de novo variations,
idiopathic disease variants, novel disease causative variants, rare
variants and common phenotypic variants.
Clinical Reports
Cloud Computing Accurate Analysis Tested & Validated Data Security
4. • Mutation Analysis for Cancer
• Orphan Disease Diagnosis
• Discover Novel Mutations
• Better Therapy Management
06
LeucineRichBioPrivateLimited
www.leucinerichbio.com
For Clinics
The Management Team
The Management Team has over 30 years of cumulative experience in
Systems Biology, Bioinformatics, Genomics,
Molecular Biology and Drug Discovery.
Kumar Sankaran – Founder & Director
– Co‐Founder & DirectorPrabhath Manjappa
–Director Business Development & InnovationDr.Debojyoti Dhar
+91 973 909 9468 info@leucinerichbio.com
In this era of personalized/precision
medicine, fast and accurate diagnosis is
key for proper prognosis and treatment
of diseases. We at Leucine Rich Bio
understand the relevance and scope of NGS
data that can deliver meaningful and
actionable information to diagnostic
companiesandclinicians.